Welcome to our dedicated page for Vaxart news (Ticker: VXRT), a resource for investors and traders seeking the latest updates and insights on Vaxart stock.
Vaxart, Inc. (symbol: VXRT) is a clinical-stage biotechnology company dedicated to transforming vaccine delivery through its innovative oral recombinant vaccine platform. Founded in 2004, Vaxart's primary focus is the development of vaccines in tablet form, offering a needle-free alternative that is easy to administer and store. This proprietary technology aims to revolutionize the global vaccine market, addressing common diseases such as Coronavirus, Norovirus, Seasonal Influenza, Respiratory Syncytial Virus (RSV), and Human Papillomavirus (HPV).
Headquartered in the United States, Vaxart operates in a single segment focused exclusively on the discovery and development of these groundbreaking oral recombinant protein vaccines. The company has made significant strides in the clinical development of its diverse pipeline, with several candidates currently undergoing trials. Vaxart’s oral vaccines are designed to simplify distribution and administration, potentially increasing vaccination rates and improving global health outcomes.
Recent achievements for Vaxart include the ongoing development and testing of its oral COVID-19 vaccine candidate, which has shown promise in preclinical studies and early-phase clinical trials. This innovation could play a crucial role in global vaccination efforts, especially in regions where cold-chain requirements pose logistical challenges. Other notable projects include the development of oral vaccines for Norovirus and Influenza, which are also advancing through various stages of clinical testing.
Financially, Vaxart remains focused on strategic partnerships and funding opportunities to support its research and development initiatives. The company's recent financial results for the full year ended December 31, 2023, and the first quarter ended March 31, 2024, reflect its ongoing commitment to advancing its oral vaccine candidates through clinical trials and towards regulatory approval.
For more information and the latest updates, contact Vaxart Media Relations: Mark Herr (mherr@vaxart.com, 203-517-8957) or Investor Relations: Andrew Blazier (IR@vaxart.com, 646-871-8486).
Vaxart, Inc. (NASDAQ: VXRT) has commenced recruiting participants for its Phase II clinical trial of an oral COVID-19 vaccine. The trial aims to enroll 96 U.S. subjects, including both COVID-19 naïve and mRNA vaccinated individuals, with dosing expected to start later this month. Vaxart plans to expand the trial internationally, beginning with India later in the year. The Phase II program is crucial for evaluating the vaccine's effectiveness, especially against emerging variants, building on promising results from prior nonhuman primate studies.
Vaxart, Inc. (NASDAQ: VXRT) announced the appointment of James F. Cummings, M.D., as Chief Medical Officer. Dr. Cummings, with extensive expertise in vaccine development, will oversee Vaxart's Phase II clinical trials for its oral COVID-19 vaccine. Vaxart aims to revolutionize vaccination with its oral tablet formulations, facilitating easier distribution and administration. The company focuses on various infectious diseases, including norovirus and flu, and is developing a broad portfolio of oral recombinant vaccines.
Vaxart (NASDAQ: VXRT) announced that senior scientist Susan Johnson, PhD, will present at ID Week 2021 (Sept 29 - Oct 3) and the 15th Vaccine Congress (Oct 4 - 6). Dr. Johnson's presentation, scheduled for Oct 5, focuses on Vaxart's COVID-19 oral vaccine candidate, highlighting its ability to induce immune responses. The ID Week conference is a collaboration among leading infectious disease organizations, while the Vaccine Congress will gather experts to discuss advancements in vaccine research.
Vaxart, Inc. (NASDAQ: VXRT) announced the formation of a Manufacturing and Quality Advisory Board, aimed at enhancing its vaccine development efforts. The board, convened on August 21, comprises six experts with extensive experience in bioprocess development, regulatory affairs, and quality assurance. CEO Andrei Floroiu expressed excitement about leveraging their insights as Vaxart progresses toward late-stage development and commercialization of its oral vaccine portfolio, which includes candidates for COVID-19 and other viral diseases.
Vaxart, Inc. (NASDAQ: VXRT) announced that CEO Andrei Floroiu and CSO Sean Tucker will present at the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021, at 10:40 a.m. ET. The presentation can be viewed here and on Vaxart's website. Vaxart is advancing its oral tablet COVID-19 vaccine into phase II trials, being the only oral COVID-19 vaccine supported by clinical data. The company develops a variety of oral recombinant vaccines and holds multiple patents for its innovative technology.
Vaxart, Inc. (Nasdaq: VXRT) announced that CEO Andrei Floroiu and CSO Dr. Sean Tucker will present at the H.C. Wainwright 23rd Annual Global Investor Conference from Sept. 13-15, 2021. The presentation will be available on demand starting at 7:00 a.m. ET on Sept. 13. Vaxart's oral tablet COVID-19 vaccine, which has completed phase I trials, is set to enter phase II trials this year, being the only oral vaccine backed by clinical data. Vaxart develops a range of oral vaccines targeting various diseases, supported by its proprietary delivery platform.
Vaxart, Inc. (NASDAQ: VXRT) announced that Dr. Julie M. Cherrington has joined its board of directors. Dr. Cherrington, an accomplished life science executive, brings extensive experience in drug development and commercialization. Her leadership background includes roles as CEO in multiple biotech firms and significant contributions to several FDA-approved products. Vaxart is advancing oral vaccines for COVID-19 and norovirus, positioning itself for transformative impacts in public health. The board expressed optimism regarding Dr. Cherrington's insights as Vaxart progresses in its clinical trials.
Vaxart, Inc. (NASDAQ: VXRT) announced the establishment of a Scientific and Clinical Advisory Board on August 19, 2021. The board includes eight experts in immunology and infectious diseases, with its first meeting held on July 24, 2021. CEO Andrei Floroiu highlighted the board's significance for advancing Vaxart's oral vaccine programs. Members include renowned figures such as Dr. Robert Belshe and Dr. Ralph Baric, who bring extensive experience in vaccine development and research. Vaxart aims to leverage this expertise to enhance public health through its innovative oral vaccine delivery platform.
On August 5, 2021, Vaxart, Inc. (Nasdaq: VXRT) released its second-quarter business update, showcasing progress in oral tablet vaccines. The company raised $36.2 million from its $250 million at-the-market facility and signed a licensing agreement with Altesa Biosciences for its antiviral, Vapendavir, potentially generating $130 million in milestone payments. Financially, Vaxart reported a revenue decrease to $112,000 and a net loss of $16.1 million, compared to $523,000 and $9.0 million in the prior year’s quarter. Research initiatives continue for COVID-19 and norovirus vaccines.
Vaxart, Inc. (NASDAQ: VXRT) announced that the U.S. FDA has cleared its Investigational New Drug application for an S-only oral tablet SARS-CoV-2 vaccine candidate. This milestone allows Vaxart to advance its first S-only vaccine construct, complementing its existing S+N construct, which has completed Phase I trials. Preliminary studies show the S-only vaccine produces higher serum antibodies compared to the S+N vaccine. The Phase II clinical trial for the S-only construct is anticipated to begin in the second half of 2021.
FAQ
What is the current stock price of Vaxart (VXRT)?
What is the market cap of Vaxart (VXRT)?
What is Vaxart, Inc. known for?
When was Vaxart, Inc. founded?
What is Vaxart's proprietary technology?
Where is Vaxart, Inc. headquartered?
What are some diseases Vaxart's vaccines target?
How is Vaxart's oral vaccine beneficial?
What recent achievements has Vaxart made?
What is Vaxart's financial condition?
How can I contact Vaxart for more information?
What segment does Vaxart operate in?
